Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Clinical Trials
249
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (211 trials with phase data)• Click on a phase to view related trials
HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC
- Conditions
- Breast Cancer
- Interventions
- Drug: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT05566457
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT05546255
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Low-dose Radiotherapy in iNHL
- Conditions
- Low-dose RadiotherapyIndolent Lymphoma
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 73
- Registration Number
- NCT05543070
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
- Conditions
- Metastatic Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaUnresectable Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT05522894
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors
- Conditions
- Advanced Tumor of Digestive Tract or Urinary System
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT05499715
- Locations
- 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 50
- Next
News
BCMA-Targeted Bispecific Antibody CM336 Shows Promise for Refractory Autoimmune Hemolytic Anemia in NEJM Study
Keymed Biosciences' CM336, a BCMA x CD3 bispecific antibody, achieved rapid partial remission in two patients with refractory autoimmune hemolytic anemia within 13-19 days of treatment.
Fruquintinib-Capecitabine Combination Shows Promise as Maintenance Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Phase 1/2 study data presented at the 2025 AACR Annual Meeting revealed promising efficacy of fruquintinib plus capecitabine as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer patients.
Toripalimab Induction Therapy Reduces Disease Progression Risk by 74% in Bulky Stage III NSCLC
Toripalimab induction therapy plus chemotherapy significantly improved progression-free survival compared to chemotherapy alone in patients with bulky, unresectable stage III non-small cell lung cancer, with 1-year PFS rates of 85.6% versus 54.5%.
Neoadjuvant Immunochemotherapy Plus Chemoradiation Improves Outcomes in Esophageal Cancer
A phase II trial showed that chemoradiation followed by immunochemotherapy and surgery improved outcomes in patients with unresectable, locally advanced esophageal squamous cell carcinoma.
Novel Immunochemotherapy Regimen Shows Promise in Unresectable Esophageal Cancer
A Phase II trial demonstrates the safety and efficacy of chemoradiotherapy followed by tislelizumab-based immunochemotherapy in patients with unresectable esophageal squamous cell carcinoma.